Devonian Health Group Announces the Recognition of Sybil Dahan, President of Altius Healthcare, as Inductee into the 2018 Canadian Healthcare Marketing Hall of Fame.
Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, announces the recognition of Sybil Dahan, President of Altius Healthcare - commercial division of Devonian - as an inductee into the 2018 Canadian Healthcare Marketing Hall of Fame.
The 2018 Annual Canadian Healthcare Hall of Fame Inductees, including Sybil Dahan of Altius Healthcare, were honored at a Gala Luncheon, on Wednesday October 24 at the Mississauga Convention Centre. The Healthcare Awards luncheon followed the Annual National Pharmaceutical Congress.
The Hall of Fame was established, by The Chronicle of Healthcare Marketing™ publication, to honor healthcare marketers who have contributed to the Pharmaceutical Marketing avocation and are an inspiration to others. “Sybil Dahan is a visionary and energetic senior level leader who effectively manages all aspects of commercial operations and has lead teams to levels of performance that they never thought were possible. We are excited she is now a key contributor within Devonian’s senior management and on behalf of the entire team, I would like to extend the warmest congratulations for this recognition of her contributions to Healthcare Marketing in Canada.” said Dr. André P. Boulet, President and Chief Executive Officer of Devonian.
Nominations for the 2018 selection of honorees were solicited during the past months from the publications’ readers and the finalists were chosen from this field of deserving candidates, but stand for, in the view of the selection committee, a representative cross-section of the qualities that make this business unique and fulfilling. “I am earnestly grateful for the recognition. Nothing is more humbling as gratifying than to be recognized by a group of peers. It is an even greater honor to be placed in such distinguished ranks as those of the past honorees, many of whom have been colleagues at one time or another, all of whom have made important contributions to our Industry in Canada.” said Sybil Dahan, President of Altius Healthcare – commercial division of Devonian Health Group Inc.
About the Altius Healthcare acquisition
Devonian is pleased to announce the closing of the acquisition of all of the issued and outstanding shares of Altius Healthcare Inc., as all pre-vesting conditions have been met or waived by Devonian.
"The acquisition brings strong sales and marketing skills to Devonian, allowing Devonian to position itself for continued growth and value to our shareholders," said Dr. André P. Boulet, President and Chief Executive Officer of Devonian.
Grant of Options
Devonian also announces that on April 6, 2018, the Board of Directors approved the grant of 250,000 options (the "Options") to certain directors and consultants of the Corporation. Each option entitles the holder to acquire one subordinate voting share in the capital of the Corporation at a price of $ 1.20 per subordinate voting share for a period of five years beginning on April 6, 2018.
Options are granted pursuant to the terms and conditions of the Corporation's current stock option plan and may be exercised immediately.
About the Canadian Healthcare Marketing Hall of Fame
The Chronicle of Healthcare Marketing™ has conducted the Canadian Healthcare Marketing Hall of Fame program since 2002. This program was conceived by the publication’s staff as a means of providing formal recognition of the leadership provided by individuals who have had extraordinary influence on the business. The criteria for Nominees are described as follows: Healthcare marketing professionals who, consistently through their careers in Canada, in the pharmaceutical, biotechnology, medical device/supply industries, or organizations which supply those industries (such as communications, educational services, advertising and marketing services) have made a lasting impact on others; or served as a source of inspiration; or have demonstrated extraordinary dedication and commitment to the humane principles inherent in our profession. The Hall of Fame selections committee evaluates nominations based on the number of nominations received for a particular nominee, the rationale for the nomination, the length of industry service by the nominee, and the number of times that a nominee has been proposed since the inception of the program. Chosen Honorees stand for, in the view of the selection committee, a representative cross-section of the qualities that make our business unique and fulfilling.
For more information visit www.pharmacongress.info/hall-of-fame/
About Altius Healthcare Inc.
Based in Concord, Ontario, Altius Healthcare is a specialty pharmaceutical company with a primary focus of acquiring and in-licensing safe and innovative medicines and healthcare products designed to help people of all ages live healthier lives. Altius then leverages its expertise in the commercialisation activities required to successfully launch and distribute these medicines in Canada. The team’s diverse experience and expertise draws from nearly 40 years of producing, importing, marketing and distributing branded and generic medicines.
For more information, visit www.altiushealthcare.ca
Devonian Health Group Inc. is a late stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2013 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Their recently acquired commercialization partner, Altius Healthcare Inc., brings opportunities for further diversification and growth potential. Devonian is traded publicly on the TSXV Exchange (TSXv:GSD).
For more information about Devonian Health Group Inc., visit www.groupedevonian.com
Forward Looking Statements
This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181112005482/en/